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Introduction
Alzheimer’s disease (AD) is the most common human neurode-
generative disorder that leads to memory loss. It is widely believed 
that AD is a multifactorial disorder affected by a mix of genetic, 
environmental, and lifestyle factors (1–3). Neuropathologically, 
AD is characterized by the presence of senile plaques and neu-
rofibrillary tangles (NFTs) (4–6). Several studies (7–13) also sug-
gest that glial activation and associated inflammation play an 
important role in the disease pathogenesis and that regulation of 
neuroinflammation may have therapeutic efficacy in attenuating 
neurodegeneration in AD.
TLRs serve as important links between innate and adaptive 
immunity primarily by responding to bacteria, bacterial prod-
ucts, viruses, viral products, and flagellin (14, 15) . Currently, 
11 different TLRs have been reported to exist in humans, and 
all the major CNS cell types are known to express TLRs (15, 16). 
However, microglia are the only cells in the CNS that express 
nearly all the TLRs known to date (16). Aside from TLR3, every 
TLR requires MyD88 for downstream signaling (14, 15). We (17) 
and others (18, 19) have shown that fibrillar Aβ peptides require 
TLR2 for microglial inflammation. Here, we demonstrated that 
TLR2 and MyD88 levels increased in vivo in the frontal cortex 
and hippocampus of patients with AD and 5XFAD mice. Since 
no option is available for specific targeting of induced TLR2, 
we designed a peptide corresponding to the TLR2-interacting 
domain of MyD88 (TIDM) that specifically inhibited induced 
TLR2 signaling and fibrillar Aβ–mediated microglial inflam-
mation without modulating dsRNA-, bacterial LPS–, flagellin-, 
1-methyl-4-phenylpyridinium– (MPP+-), or CpG DNA–medi-
ated microglial activation. Moreover, intranasal administra-
tion of TIDM peptide resulted in a reduction in hippocampal 
microglial activation, lowering of the Aβ load, suppression of 
neuronal apoptosis, and improvement in memory and learning 
in 5XFAD mice, highlighting the therapeutic promise of the 
TIDM peptide in AD.
Results
Upregulation of TLR2 in AD. To investigate the role of TLR2 in the 
pathogenesis of AD, we monitored the level of TLR2 by immuno-
blot analysis of prefrontal cortex (PFC) (Brodmann area 9) cells 
from 33 subjects who died with AD dementia (n = 10) or mild cog-
nitive impairment (MCI) (n = 11) and from age-matched individ-
uals with no cognitive impairment (NCI) (n = 12) (Supplemental 
Table 1; supplemental material available online with this article; 
https://doi.org/10.1172/JCI96209DS1). We found no significant 
differences across the groups in terms of age, sex, postmortem 
interval, brain weight, and Braak scores (Supplemental Table 1). 
Induction of TLR2 activation depends on its association with the adapter protein MyD88. We have found that TLR2 and 
MyD88 levels are elevated in the hippocampus and cortex of patients with Alzheimer’s disease (AD) and in a 5XFAD mouse 
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experimental allergic encephalomyelitis and collagen-induced arthritis. Therefore, selective targeting of the activated status 
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els did not significantly differ across the groups (Figure 1, A and 
D; Supplemental Table 2). The Spearman rank-order correlation 
showed that both TLR2 and MyD88 levels in PFC were positively 
correlated with Braak staging (Figure 1, E and F, and Supplemen-
tal Table 2). On the other hand, we found no relationship between 
TLR4 levels and Braak score (Figure 1G and Supplemental Table 
For comparison, we included TLR4. Since all the TLRs except 
TLR3 use MyD88, we also investigated MyD88. We found that the 
levels of both TLR2 and MyD88 in PFC were significantly altered 
among the groups, with AD subjects expressing higher levels of 
TLR2 and MyD88 relative to levels in the NCI and MCI subjects 
(Figure 1, A–C and Supplemental Table 2). In contrast, TLR4 lev-
Figure 1. Monitoring TLR2, TLR4, and MyD88 levels in the CNS of individuals clinically diagnosed with NCI, MCI, or AD. (A) PFC homogenates (25 μg) 
from NCI (light blue), MCI (dark blue), and AD (gray) individuals were immunoblotted for TLR2, TLR4, and MyD88. Actin was used to normalize the signals 
obtained by densitometric measurement (ImageJ). Coomassie was used to verify protein loading. Twelve NCI, eleven MCI, and ten AD samples were run in 
three independent experiments. (B) MyD88 levels were significantly elevated in AD subjects relative to levels in both NCI and MCI (***P < 0.001; Krus-
kal-Wallis test) subjects. (C) TLR2 levels were significantly higher in AD compared with MCI subjects. *P < 0.05; Kruskal-Wallis test. (D) TLR4 levels did not 
differ significantly across the 3 groups. (E) MyD88 (0.371, P = 0.033) and (F) TLR2 (0.463, P = 0.007) were positively correlated with the Braak score by Krus-
kal-Wallis test. (G) No such correlation was found between TLR4 (–0.012, P = 0.947) and the Braak score. (H) MyD88 was negatively correlated with MMSE 
scores (–0.538, P = 0.001) and the (I) GCS index (–0.475, P = –0.005). However, the negative correlation was not significant for TLR2 with (J) the MMSE 
(–0.278, P = 0.117) or (K) the GCS (–0.177, P = 0.326). TLR4 was also not negatively correlated with (L) the MMSE (–0.173, P = 0.336) or (M) the GCS (0.047,  
P = 0.794). Statistical significance was determined by Spearman’s rank-order test in G–M. Hippocampal sections of NCI and AD brains were double labeled 
with Iba-1 (microglia) and TLR2, TLR4, or MyD88. Cells positive for TLR2 (N, cortex; O, CA1), MyD88 (P, cortex; Q, CA1), and TLR4 (R, cortex; S, CA1) were 
counted in 2 sections (2 images/slide) of each of 4 different cases. †P < 0.001 versus NCI; 2-sample t test. Data represent the mean ± SEM.
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hippocampus of Tg mice as compared with age-matched non-Tg 
mice. We also found increased Iba-1 immunoreactivity and colo-
calization of many Iba-1–positive cells with TLR2 (Supplemental 
Figure 2B) and MyD88 (Supplemental Figure 3B) in the cortex 
and hippocampus of Tg mice. Western blot experiments also con-
firmed the increase in TLR2 (Supplemental Figure 2, C and D) and 
MyD88 (Supplemental Figure 3, C and D) levels in the hippocam-
pus of Tg mice as compared with levels in non-Tg mice.
Design of a peptide corresponding to the TIDM for specific tar-
geting of TLR2. Since there is no specific inhibitor of TLR2, for 
therapeutic purposes, we attempted to target TLR2. After ligand 
binding, TLR2 functions through MyD88 (14, 15). Therefore, we 
applied a rigid-body, protein-protein interaction tool to model 
the interaction between the TLR-interacting domain (TIR) of 
TLR2 and MyD88. Since the crystal structures of TIRs of murine 
TLRs were not available, we adopted an silico homology model-
ing strategy to build 3D structures of TIRs from all different TLRs 
(Supplemental Figure 4, A–G). Similar to previous findings (20), 
2). Importantly, MyD88 was also negatively correlated with the 
mini–mental state examination (MMSE) and global cognitive Z 
score (GCS) (Figure 1, H–M, and Supplemental Table 2).
To confirm these findings, we performed double-label immu-
nofluorescence analysis of hippocampal sections. As expected, 
Iba-1 (a microglial marker) levels were higher in the cortex and 
hippocampus of AD cells as compared with levels in NCI cells 
(Supplemental Figure 1, A–E). As with the Western blot results, we 
detected higher levels of TLR2 (Supplemental Figure 1A and Fig-
ure 1, N and O) and MyD88 (Supplemental Figure 1B and Figure 
1, P and Q) in the cortex and hippocampus of AD brain compared 
with levels in NCI brain. Again, there was no difference in TLR4 
expression (Supplemental Figure 1C and Figure 1, R and S).
Upregulation of TLR2 in 5XFAD-Tg mice. Next, we examined 
the status of TLR2 and MyD88 in the hippocampus of 5XFAD-Tg 
mice. As with levels in the CNS of AD subjects, we noticed higher 
levels of TLR2 (Supplemental Figure 2, A and B) and MyD88 (Sup-
plemental Figure 3, A and B) in cortex and different parts of the 
Figure 2. Design of a peptide for disruption of TLR2 and MyD88 interaction. (A) A rigid-body, in silico docked pose of mouse TLR2 (blue) and MyD88 
(green) (electrostatic energy = –7.750 kcal/mol; desolvation energy = –24.99 kcal/mol; VDW energy = 105.25 kcal/mol; total energy = –22.216 kcal/mol) 
shows strong interaction between amino acids 245 and 250 of the CD loop of MyD88 and the BB loop of TLR2. Therefore, the peptide corresponding to this 
domain of MyD88 (TIDM) was used to dissociate the interaction between TLR2 and MyD88. (B) TLR2-MyD88 interaction was complexed with the WT TIDM 
peptide (electrostatic energy = –4.516 kcal/mol; desolvation energy = –24.027 kcal/mol; VDW energy = 16.724 kcal/mol; total energy = –26.871 kcal/mol). (C) 
Generation of a cMyc-tagged cTLR2 recombinant protein. Amp, ampicillin resistance. The in vitro binding affinity of increasing doses of WT TIDM (D) and 
mTIDM (E) with cTLR2 was examined using SPR analyses (n = 2 replicates/dose in 3 independent experiments). (F) Plot of the binding response values ver-
sus the concentrations of WT TIDM (circles) and mTIDM (squares) peptides. (G) Melting curve of cTLR2 protein (black) alone and with WT TIDM peptides 
(green). Thermal shift analyses showed a 4.96°C shift of the melting temperature (ΔTm) (n = 2 replicates/dose in 3 independent experiments). (H) Melting 
curve of cTLR2 protein (black) alone and with mTIDM peptides (red) indicated a ΔTm of 0.87°C (n = 2 replicates/dose in 3 independent experiments). μRIU, 
micro refractive index units. Data represent the mean ± SEM.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
4 3 0 0 jci.org   Volume 128   Number 10   October 2018
for mTIDM (Figure 2H). Together, these results suggest that WT 
TIDM is a potent small-molecule peptide that strongly interferes 
with the interaction between TLR2 and MyD88.
Next, we examined whether WT TIDM had similar affinity for 
other TLRs. Interestingly, our in silico analyses revealed that the 
WT TIDM peptide docked far from the BB loop of TLR1 (Figure 
3A), TLR4 (Figure 3B), TLR5 (Figure 3C), TLR6 (Figure 3D), TLR7 
(Figure 3E), and TLR9 (Figure 3F), suggesting that WT TIDM spe-
cifically targets the BB loop of TLR2, but not other TLRs.
Next, we examined whether the WT TIDM peptide could 
disrupt the physical association between endogenous TLR2 and 
MyD88. Earlier, we delineated that fibrillar Aβ1-42 activates 
microglia via TLR2 (17). We performed immunoblot analysis of 
MyD88 immunoprecipitates with antibodies against TLR2 and 
found that fibrillar Aβ1-42 treatment increased the association 
between TLR2 and MyD88 in microglial cells and that this interac-
tion was inhibited by WT TIDM, but not mTIDM, peptide (Figure 3, 
G and H). Input showed the presence of equal amounts of TLR2 and 
MyD88 under different treatment conditions (Figure 3G). To under-
stand the specificity, we examined the effect of WT TIDM peptide 
on the interaction between TLR4 and MyD88. LPS is a prototypical 
agonist of TLR4. LPS treatment increased the association between 
TLR4 and MyD88 in microglial cells (Figure 3, I and J) and in con-
trast to the suppression of TLR2-MyD88 interaction (Figure 3, G 
and H), WT TIDM peptide had no effect on the interaction between 
TLR4 and MyD88 (Figure 3, I and J). Next, we examined whether 
WT TIDM could interfere with the interaction between MyD88 and 
newly formed Myc-tagged cTLR2. Therefore, microglial cells were 
transduced with pLenti-cMyc-cTlr2 lentivirions, and after 48 hours 
of transduction, cells were treated with fibrillar Aβ1-42 in the pres-
ence or absence of WT TIDM or mTIDM for 1 hour. Immunoblot 
analysis of MyD88 immunoprecipitates with antibodies against 
cMyc showed that the interaction between newly formed cTLR2 
and MyD88 in Aβ1-42–treated microglial cells was inhibited by WT 
TIDM, but not mTIDM, peptide (Figure 3, K and L).
TIDM peptide inhibits microglial inflammation induced by fibril-
lar Aβ1-42 and lipoteichoic acid, but not 1-methyl-4-phenylpyridini-
um, dsRNA (poly IC), bacterial LPS, flagellin, or CpG DNA. Microglia 
expressing different TLRs are activated under various pathological 
conditions, such as neurodegeneration, inflammation, and viral 
or bacterial infection. (7, 21). Therefore, we investigated whether 
TIDM peptide was capable of suppressing microglial activation 
induced by different stimuli. Microglial cells pretreated with dif-
ferent concentrations of WT TIDM and mTIDM peptides for 1 
hour were stimulated with fibrillar Aβ1-42 (an etiological reagent 
of AD), 1-methyl-4-phenylpyridinium (MPP+) (Parkinsonian tox-
in), lipoteichoic acid (LTA) (agonist of TLR2), poly IC (agonist of 
TLR3), LPS (agonist of TLR4), flagellin (agonist of TLR5), or CpG 
DNA (agonist of TLR9). As expected, fibrillar Aβ (Figure 4A), MPP+ 
(Figure 4D), LTA (Figure 4G), poly IC (Supplemental Figure 7A), 
LPS (Figure 4J), flagellin (Figure 4M), and CpG DNA (Figure 4P) 
induced the activation of NF-κB in microglial cells. However, WT 
TIDM peptides inhibited fibrillar Aβ- and LTA-mediated activa-
tion of NF-κB (Figure 4, A and G). In contrast, WT TIDM peptides 
remained unable to suppress the activation of NF-κB in microglial 
cells induced by MPP+ (Figure 4D), poly IC (Supplemental Figure 
7A), LPS (Figure 4J), flagellin (Figure 4M), or CpG DNA (Figure 
the docked pose of the MyD88 and TIR complex as derived from 
our in silico modeling analyses revealed that the BB loop of TLR2 
was engaged with the CD loop of MyD88, with a strong van der 
Waals (VDW) interaction (Figure 2A). Therefore, we designed the 
following peptides corresponding to the TIDM from the CD loop 
to disrupt the interaction between TLR2 and MyD88: WT TIDM, 
drqikiwfqnrrmkwkk245PGAHQK250 and mutated TIDM (mTIDM), 
drqikiwfqnrrmkwkk245PGWHQD250.
We added the Antennapedia homeodomain (lowercase) at the 
C-terminal of these peptides to facilitate cell permeability. MyD88 
segments are in uppercase, and the positions of the mutations are 
underlined. Interestingly, when the interaction between the TIR 
of TLR2 and MyD88 was modeled with the WT TIDM peptide, 
we observed that MyD88 was associated with a certain degree of 
rotation, leaving its CD loop far removed from the TLR2 BB loop 
(Figure 2B). According to pyDock analysis, the WT TIDM peptide 
was found to be docked in the interface of the CD loop, αB helix, 
and BB loop of the TIR domain of TLR2 (Supplemental Figure 
5A). That specific pose of the WT TIDM peptide imposed its VDW 
surface to be distributed over the BB loop of TLR2 (Supplemen-
tal Figure 5A), which was not possible in the case of the mTIDM 
peptide (Supplemental Figure 5B). We observed a strong electro-
static interaction (2.31 A°) between the NE1 atom of the conserved 
histidine residue (H82) of the CD loop and the ND atom of the 
histidine (H4) residue of the WT TIDM peptide (Supplemental 
Figure 5C). The docked structures of mTIDM with TLR2 clearly 
indicated that there was a very weak electrostatic interaction (7.26 
A°) between the H82 residue of the CD loop and the H4 residue 
of the mTIDM peptide (Supplemental Figure 5C; right). Moreover, 
mutation of WT TIDM from lysine to aspartate imposed a nega-
tive cloud, which also drove the C-terminal end of mTIDM even 
further away from the BB loop and more toward the groove of the 
αB helix (Supplemental Figure 5B). We also assessed the possibil-
ity of VDW interaction in that complex by measuring the distance 
of VDW droplets between 2 close residues of TLR2 and MyD88 
(Supplemental Figure 5D). We observed a significant VDW over-
lap between MyD88 and TLR2 in the absence of WT TIDM. How-
ever, when complexed with WT TIDM, the BB loop of TLR2 and 
the CD loop of MyD88 posed far away from each other, negating 
any possibility of VDW interaction (Supplemental Figure 5E). To 
compare the affinity of WT TIDM and mTIDM for TLR2 from 
another angle, we performed surface plasmon resonance (SPR) 
analysis. We first cloned and purified the whole TLR2 protein. 
However, it was not stable, and since the whole TLR2 protein was 
also not available, we prepared only the C-terminal TIR domain of 
TLR2 protein (cTLR2) using a viral cloning strategy and purified 
the protein by Myc affinity column (Figure 2C). Kinetic plots (Fig-
ure 2, D and E) clearly demonstrated that increasing doses of both 
WT TIDM and mTIDM showed binding with cTLR2. However, 
WT TIDM displayed much stronger affinity than mTIDM toward 
cTLR2 (Figure 2, D–F). According to the plot of the SPR response 
at equilibrium versus peptide concentration (Figure 2F), the affini-
ty of WT TIDM (KD = 8 μM) for cTLR2 was approximately 2.5 times 
stronger than that of mTIDM (KD= 19 μM). To further substantiate, 
we performed a thermal shift assay, which revealed that 10 μM of 
WT TIDM peptide strongly shifted the melting curve of cTLR2 
(Figure 2G). On the other hand, very little shifting was observed 
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Figure 3. Selective disruption of TLR2 and MyD88 interaction by WT TIDM. In silico analyses of interactions of WT TIDM with TLR1, TLR4, TLR5, TLR6, 
TLR7, and TLR9. Rigid-body interaction analyses were performed using the pyDock in silico analysis tool. Complexes of TLR1–WT TIDM (A), TLR4–WT 
TIDM (B), TLR5–WT TIDM (C), TLR6–WT TIDM (D), TLR7–WT TIDM (E), and TLR9–WT TIDM (F) are shown. (G) BV-2 microglial cells preincubated with WT 
TIDM and mTIDM peptides for 1 hour were stimulated with 1 μM fibrillar Aβ1-42 (fAβ) under serum-free conditions. After 1 hour, cellular extracts were 
immunoprecipitated (IP) with an anti-MyD88 antibody, followed by Western blotting of immunoprecipitates for TLR2. As a control, cellular extracts 
were immunoprecipitated with normal IgG. Input was also immunoblotted (IB) with TLR2 and MyD88. (H) Bands were scanned, and values (TLR2/input) 
are presented relative to the control (n = 2 replicates/condition in 3 independent experiments). ***P < 0.001; 2-sample t test. Results were analyzed 
by 2-sample t test. (I) BV-2 microglial cells preincubated with WT TIDM and mTIDM peptides for 1 hour were stimulated with LPS under serum-free 
condition. After 1 hour, cellular extracts were immunoprecipitated with an anti-MyD88 antibody, followed by Western blotting of immunoprecipitates 
for TLR4. As a control, cellular extracts were immunoprecipitated with normal IgG. Input was also immunoblotted with TLR4 and MyD88. (J) Bands were 
scanned, and values (TLR4/input) are presented relative to the control (n = 2 replicates/condition in 3 independent experiments). ***P < 0.001; 2-sample 
t test. (K) BV-2 microglial cells were transduced with pLenti-cMyc-cTlr2 lentivirions, and 48 hours after transduction, cells were treated with WT TIDM 
and mTIDM for 1 hour, followed by stimulation with fibrillar Aβ1-42. After 1 hour, cellular extracts were immunoprecipitated with anti-MyD88 antibody, 
followed by Western blotting of immunoprecipitates for cMyc. Immunodepleted (ID) fractions were also immunoblotted for cMyc as a control. (L) Bands 
were scanned and values (cMyc/input) presented relative to the control (n = 2 replicates/condition in 3 independent experiments). *P < 0.05 and **P < 0.01; 
2-sample t test. Data represent the mean ± SEM.
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4P). These results were specific, as mTIDM peptides had no effect 
on the activation of NF-κB induced by any of the stimuli. Activa-
tion of the classical NF-κB pathway involves the phosphorylation 
of IκBα, followed by nuclear translocation of p65 and p50. There-
fore, we also investigated the effect of WT TIDM peptide on nucle-
ar translocation of p65 and p50 in activated microglia. As expect-
ed, we observed increased nuclear translocation of p65 and p50 
in microglial cells in response to fibrillar Aβ1-42 (Supplemental 
Figure 8, A–C) and LPS (Supplemental Figure 8, D–F). However, 
WT TIDM peptide treatment inhibited the nuclear translocation 
of p65 and p50 in microglial cells stimulated with fibrillar Aβ1-42 
(Supplemental Figure 8, A–C), but not LPS (Supplemental Figure 
8, D–F), indicating the specificity of the WT TIDM peptide. To con-
firm these results, we also monitored the expression of IL-1β and 
Figure 4. Effect of WT TIDM and mTIDM peptides on the induction of NF-κB activation and expression of proinflammatory molecules in microglial 
cells. BV-2 microglial cells preincubated with 10 μM WT TIDM or mTIDM peptides for 1 hour were stimulated with (A–C) 1 μM fibrillar Aβ1-42, (D–F) 1 μM 
MPP+, (G–I) 250 ng/ml LTA, (J–L) 1 μg/ml LPS, (M–O) 1 μM flagellin, and (P–R) 1 μM CpG DNA under serum-free conditions. After 1 hour of stimulation, 
NF-κB activation was monitored in nuclear extracts by EMSA (A, fibrillar Aβ; D, MPP+; G, LTA; J, LPS; M, flagellin; P, CpG DNA). After 4 hours of stimula-
tion, mRNA expression of IL-1β (B, E, H, K, N, and Q) and iNOS (C, F, I, L, O, and R) was monitored by real-time PCR. n = 2 replicates/dose in 3 independent 
experiments. †P < 0.001 versus control; ††P < 0.001 versus stimuli; 2-sample t test. ODN, oligodeoxynucleotide. Data represent the mean ± SEM.
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inducible NO synthase (iNOS), proinflammatory molecules that 
are driven by NF-κB activation. All stimuli induced the expression 
of IL-1β and iNOS in microglial cells (Figure 4, B, C, E, F, H, I, K, 
L, N, O, Q, and R, Supplemental Figure 6, A–F, and Supplemental 
Figure 7, B–D). Consistent with the effect of WT TIDM on NF-κB 
activation, WT TIDM peptides inhibited the expression of proin-
flammatory molecules induced only by fibrillar Aβ (Supplemental 
Figure 6A and Figure 4, B and C) or LTA (Supplemental Figure 6C 
and Figure 4, H and I), but not MPP+ (Supplemental Figure 6B and 
Figure 4, E and F), poly IC (Supplemental Figure 7, B–D), LPS (Sup-
plemental Figure 6D and Figure 4, K and L), flagellin (Supplemen-
tal Figure 6E and Figure 4, N and O), or CpG DNA (Supplemental 
Figure 6F and Figure 4, Q and R). These results suggest that the 
WT TIDM peptide specifically inhibits microglial inflammation 
induced by agonists of TLR2, but not of other TLRs.
WT TIDM peptide does not inhibit fibrillar Aβ1-42–induced acti-
vation of microglia in the absence of TLR2. Since WT TIDM peptide 
disrupted the physical association between TLR2 and MyD88, as a 
mechanistic proof of principal, we examined the effect of WT TIDM 
peptide on Aβ1-42–induced activation of Tlr2–/– microglia. As with 
BV-2 microglial cells, fibrillar Aβ1-42 peptides strongly induced the 
activation of NF-κB in primary microglia isolated from WT mice, 
and this was inhibited by WT TIDM peptide (Supplemental Figure 
9A). On the other hand, fibrillar Aβ1-42 peptides weakly induced 
the DNA-binding activity of NF-κB in Tlr2–/– microglia (Supple-
mental Figure 9A). However, in contrast to what was observed in 
WT microglia, the WT TIDM peptide remained unable to inhibit 
fibrillar Aβ1-42–induced activation of NF-κB in Tlr2–/– microglia 
(Supplemental Figure 9, A and B). To further confirm our findings, 
we also measured the levels of common proinflammatory cytokines 
(TNF-α and IL-1β) in supernatants. As with NF-κB activation, the 
induction of TNF-α and IL-1β production by fibrillar Aβ1-42 was low 
in Tlr2–/– microglia as compared with WT microglia (Supplemental 
Figure 9, C–F). However, the WT TIDM peptide inhibited fibrillar 
Aβ1-42 peptide–induced production of TNF-α and IL-1β in WT, but 
not Tlr2–/–, microglia (Supplemental Figure 9, C–F), suggesting that 
the WT TIDM peptide needs TLR2 to function.
Intranasal administration of WT TIDM peptide inhibits inflam-
mation, reduces plaque load, and decreases hyperphosphorylation of 
tau in the hippocampus of 5XFAD-Tg mice. It is becoming clear that 
glial inflammation plays an important role in the loss of neurons 
in AD and other neurodegenerative disorders (7, 9, 22–24). Since 
the WT TIDM peptide specifically inhibited fibrillar Aβ1-42–medi-
ated microglial activation, we decided to test its therapeutic trans-
latability in 5XFAD-Tg mice. We first determined whether the WT 
TIDM peptide could enter into the hippocampus. Tg mice were 
treated with TIDM peptides intranasally, and after 60 minutes of 
administration, we detected WT TIDM peptide in the hippocam-
pus of Tg mice by electrospray ionization–coupled mass spectrom-
etry (ESI-MS) (Figure 5, A and C). In contrast, the hippocampus of 
saline-treated Tg mice showed no peak for WT TIDM peptide (Fig-
ure 5B). The level of WT TIDM peptide was 23.33 ± 14.14 ng/g brain 
tissue in the hippocampus of WT TIDM–treated Tg mice compared 
with nil in the saline-treated Tg mice. By infrared scanning, we also 
detected TIDM peptide in hippocampus after intranasal treatment 
(Supplemental Figure 10). Therefore, after intranasal administra-
tion, TIDM peptide entered into the hippocampus.
Next, we investigated whether intranasally administered 
TIDM peptide was capable of modulating NF-κB activation in the 
hippocampus of Tg mice. As seen by double-label immunofluores-
cence of hippocampal sections, the levels of Iba-1 and phosphory-
lated p65 (p-p65) were markedly higher in Tg mice than in non-Tg 
mice (Figure 5, D–H). However, intranasal treatment of Tg mice 
with WT TIDM, but not mTIDM, peptides led to the suppression 
of both Iba-1 and p-p65 in the hippocampus of Tg mice (Figure 5, 
D–H). This was also confirmed by Western blot analysis of hippo-
campal tissues (Supplemental Figure 11, A and B). Moreover, acti-
vated microglia are known to express iNOS (21, 25). Accordingly, 
we found that hippocampal microglia of Tg mice were also posi-
tive for iNOS (Supplemental Figure 12 and Figure 5, I and J). How-
ever, WT TIDM, but not mTIDM, peptide suppressed the expres-
sion of iNOS in the hippocampus of Tg mice (Supplemental Figure 
12 and Figure 5, I and J). Western blot analysis also confirmed the 
inhibition of hippocampal iNOS expression by treatment with WT 
TIDM, but not mTIDM, peptide (Figure 5, K and L).
Amyloid plaque is an important feature of AD pathology, 
which is modeled in 5XFAD-Tg mice (26, 27). Therefore, we next 
examined whether WT TIDM treatment is capable of reducing the 
load of amyloid plaques from the hippocampus of Tg mice. Immu-
nostaining of hippocampal sections with 82E1 mAb (Figure 5, 
M–O) as well as Western blot analysis of hippocampal tissue with 
6E10 mAb (Figure 5, P and Q) and 82E1 mAb (Supplemental Fig-
ure 13, A and B) showed markedly higher levels of Aβ peptides in 
the hippocampus of Tg mice compared with levels in non-Tg mice. 
Likewise, ELISA of serum (Supplemental Figure 14, A and B), 
TBS-extracted hippocampal fractions (Supplemental Figure 14, C 
and D), and TBS plus Triton X-100–extracted hippocampal frac-
tions (Supplemental Figure 14, E and F) also revealed a marked 
increase in Aβ1-40 and Aβ1-42 in Tg mice compared with non-Tg 
mice. However, a significant decrease in Aβ was seen with WT 
TIDM, but not mTIDM, treatment (Supplemental Figure 13, A and 
B; Supplemental Figure 14, A–F; and Figure 5, M–Q). These results 
suggest that intranasal administration of WT TIDM is capable of 
reducing Aβ burden in the hippocampus of 5XFAD mice.
Hyperphosphorylation of tau is another prominent feature of 
AD pathology (28, 29). It has been shown that hyperphosphoryla-
tion of tau at Ser396 occurs in the hippocampus of 5XFAD mice at a 
much earlier stage than does the appearance of learning and mem-
ory impairment (30). Therefore, we examined the effect of TIDM 
peptide treatment on the status of tau phosphorylation in vivo in the 
hippocampus of Tg mice. Immunoblot analysis indicated a marked 
increase in p-tau in hippocampal extracts from Tg mice as compared 
with levels in extracts from non-Tg mice (Supplemental Figure 15, 
A and B). However, treatment of Tg mice with WT TIDM, but not 
mTIDM, peptide led to the suppression of p-tau in the hippocam-
pus, without affecting the total level of tau protein (Supplemental 
Figure 15, A and B), indicating that WT TIDM peptide treatment is 
adequate for decreasing p-tau in the hippocampus of Tg mice.
Reduction in neuronal apoptosis and protection of memory and 
learning in 5XFAD-Tg mice by intranasal administration of WT 
TIDM peptide. Since neuroinflammation may be associated with 
neuronal apoptosis, we next examined whether WT TIDM peptide 
treatment was able to reduce neuronal apoptosis in the hippocam-
pus of Tg mice. A number of TUNEL-positive bodies colocalized 
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Likewise, on the T-maze test, untreated Tg mice also had fewer 
positive turns (P < 0.001 [= 0.0000440]) and a higher number 
of negative turns (P < 0.001 [= 0.000223]) than did age-matched 
non-Tg mice (Figure 6, L and M). However, WT TIDM treatment 
had a significant effect on the number of successful positive turns 
(F3,28 = 31.475, P < 0.001 [= 0.0000411]) (Figure 6L) and also 
resulted in fewer errors (F3,28 = 26.653, P < 0.001 [= 0.0000235]) 
(Figure 6M) by Tg mice. Again, WT TIDM–treated mice had a 
higher number of positive turns (P < 0.001 [= 0.0000954]) and 
fewer negative turns (P < 0.001 [= 0.000123]) as compared with 
mTIDM-treated Tg mice (Figure 6, L and M). We also monitored 
the short-term memory of Tg mice using the novel object recogni-
tion (NOR) test. Tg mice exhibited significant deficits (P < 0.001 
[= 0.0000149]) in the NOR test as evidenced by the discrimina-
tion index (Figure 6N) compared with age-matched non-Tg mice. 
However, WT TIDM peptide–treated mice showed significant 
improvement (P < 0.001) in short-term memory as compared with 
either the untreated Tg or mTIDM-treated Tg mice (Figure 6N). 
On the other hand, the gross motor activity of Tg and non-Tg mice 
was nearly similar (Supplemental Figure 16). Furthermore, neither 
the WT TIDM nor the mTIDM peptide modulated the gross motor 
activity of Tg mice, as evidenced by the number of movements, 
horizontal activity, rest time, and stereotypy (Supplemental Figure 
16, A–D), suggesting that improvement of memory by WT TIDM 
peptide treatment is not due to alterations in gross motor activity.
WT TIDM peptide requires TLR2 to reduce plaques and improve 
memory in 5XFAD-Tg mice. To confirm that the WT TIDM peptide 
does in fact require TLR2 to exert its function in vivo, we crossed 
Tlr2–/– mice with Tg mice to create 5XFAD mice null for Tlr2 (Tlr2–/–
-Tg mice). Knockdown of Tlr2 did not alter the insertion or expres-
sion of the 5XFAD transgenes, and vice versa (Supplemental Figure 
17A). Six-month-old WT, Tlr2–/–, Tg, and Tlr2–/–-Tg mice did not dif-
fer significantly with respect to gross BW or wet brain weights (Sup-
plemental Figure 17, B and C). We also did not find any overt phe-
notypic differences, including diet, fecal boli, social interaction, or 
agitation across genotypes at this age. Although WT TIDM peptide 
reduced plaque load and improved spatial learning and memory 
in Tg mice (Figure 5 and Figure 6), it remained unable to do so in 
Tlr2–/–-Tg mice (Supplemental Figure 17, D–G), indicating that WT 
TIDM peptide is ineffective in the absence of Tlr2.
WT TIDM, but not mTIDM, peptide suppresses the disease pro-
cess of experimental allergic encephalomyelitis and collagen-induced 
arthritis in mice. As an important member of the innate immune 
pathways, Myd88-dependent TLR2 signaling plays a significant 
role in the pathogenesis of a wide variety of infectious and auto-
immune disorders (31, 32). Therefore, we examined whether WT 
TIDM peptide function is limited only to 5XFAD mice or whether 
it has effects in other disease models as well. Experimental allergic 
encephalomyelitis (EAE) is a widely used animal model of multiple 
sclerosis, and a chronic form of EAE is modeled in male C57/BL6 
mice upon immunization with MOG35-55. Like its effect in 5XFAD 
mice, intranasal treatment of EAE mice with WT TIDM peptide 
strongly inhibited the clinical symptoms of EAE (Figure 7A). When 
we compared the means between groups with Dunnett’s multiple 
comparisons analyses, we found that there was a significant dif-
ference of means between EAE and EAE plus WT TIDM (adjusted 
P < 0.001). On the other hand, the mTIDM peptide had no effect 
with NeuN in the hippocampus of Tg mice compared with that 
seen in non-Tg mice (Figure 6, A–C). However, WT TIDM, but not 
mTIDM, peptide attenuated neuronal apoptosis in the hippocam-
pus (Figure 6, A–C). This result was confirmed by the detection of 
cleaved caspase 3. As expected, cleaved caspase 3 levels increased 
in the hippocampus of Tg mice (Figure 6, D and E). However, treat-
ment of Tg mice with WT TIDM, but not mTIDM, peptide reduced 
the elevated levels of cleaved caspase 3 in the hippocampus (Fig-
ure 6, D and E), suggesting that WT TIDM peptide treatment is 
capable of decreasing neuronal apoptosis in vivo in the hippocam-
pus of Tg mice. Accordingly, the levels of plasticity-related mole-
cules (PSD95, NR2A, and GluR1) decreased in the hippocampus 
of Tg mice as compared with levels in non-Tg mice (Figure 6, F–I). 
However, consistent with the suppression of neuronal apoptosis, 
treatment of Tg mice with WT TIDM, but not mTIDM, peptide led 
to significant restoration of PSD95, NR2A, and GluR1 protein lev-
els in vivo in the hippocampus (Figure 6, F–I).
The ultimate objective of neuroprotection in AD is to improve 
and/or protect memory. Major functions of the hippocampus are 
to generate and organize long-term memory and spatial learn-
ing. Therefore, we examined whether WT TIDM peptide pro-
tected memory and learning in Tg mice. As expected, Tg mice 
took much longer to find the food reward hole and had greater 
latency (P < 0.001 [= 0.0000213]) with higher errors (P < 0.001 
[= 0.0000251]) in the Barnes maze as compared with non-Tg 
mice. However, WT TIDM treatment significantly improved the 
memory function of Tg mice, as shown by their latency (F3,28 = 
93.153, P < 0.001 [= 0.0000112]) (Figure 6J) and number of errors 
(F3,28 = 36.339, P < 001 [= 0.0000863]) (Figure 6K). Memory func-
tions of the WT TIDM peptide–treated mice were also better, as 
demonstrated by their ability to locate the reward hole with less 
latency (P < 0.001 [= 0.0000600]) and fewer errors (P < 0.001 
[= 0.0000579]) when compared with mTIDM-treated mice. 
Figure 5. After intranasal delivery, WT TIDM peptide enters into the 
hippocampus and suppresses glial activation and reduces plaques in the 
hippocampus of Tg mice. Tg mice (6 months of age) received 1 intranasal 
dose of WT TIDM peptide (0.1 mg/kg BW). After 60 minutes of treatment, 
mice were perfused with sterile saline, and hippocampi were homogenized 
and supernatant analyzed for WT TIDM by ESI-MS (A, WT TIDM standard; 
B, untreated 5XFAD-Tg; C, WT TIDM–treated 5XFAD-Tg). Tg mice were 
treated with WT TIDM and mTIDM peptides (0.1 mg/kg body WT/2d) via the 
intranasal route. After 30 days, hippocampal sections were double labeled 
for Iba-1 and p-p65 (D) and Iba-1 and iNOS (Supplemental Figure 9). Cells 
positive for Iba-1 (E, CA1; F, CA3), p-p65 (G, CA1; H, CA3), and iNOS (I, CA1; 
J, CA3) were counted in 2 sections (2 images/slide) from each of 6 different 
mice (n = 6) per group. †P < 0.001 versus non-Tg; ††P < 0.001 versus Tg; 
2-sample t test. (K) Hippocampal extracts from all groups of mice (n = 4 per 
group) were immunoblotted for iNOS. Actin was run as a loading control. 
Bands were scanned, and values (L, iNOS/actin) are presented relative to 
the non-Tg control. †P < 0.001 versus non-Tg; ††P < 0.001 versus Tg; 2-sample 
t test. (M) Hippocampal sections were immunolabeled with 82E1 mAb. 
Amyloid plaques (N, cortex; O, hippocampus) were counted in 2 sections 
(2 images/slide) from each of 6 different mice per group. †P < 0.001 versus 
non-Tg; ††P < 0.001 versus Tg; 2-sample t test. (P) Hippocampal extracts  
(n = 4 per group) were analyzed for Aβ by Western blotting using 6E10 mAb. 
Arrowhead indicates a 4-kDa Aβ band. MW, molecular weight. (Q) Bands 
were scanned, and values (Aβ/actin) are presented relative to the non-Tg 
control. †P < 0.001 versus non-Tg; ††P < 0.001 versus Tg; 2-sample t test.  
ve, vehicle. Scale bars: 100 μm. Data represent the mean ± SEM.
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direct interaction between TLR2 and Aβ or via CD14 (18, 19, 33). 
Here, we describe an important role of TLR2 in AD. We detected 
higher levels of TLR2 in the hippocampus and PFC of individu-
als with AD dementia versus those with MCI or NCI. Although 
some studies reported the involvement of TLR4 in Aβ-mediated 
microglial activation, we did not find higher levels of TLR4 in the 
CNS of individuals with AD dementia, indicating the specificity 
of our finding. Tlr2 polymorphism has been reported to influence 
susceptibility to AD (34), and peripheral blood mononuclear cells 
(PBMCs) from patients with AD also express increased levels of 
TLR2 (35). Consistent with what was observed withTLR2, we 
also detected the upregulation of MyD88 in the CNS of individu-
als with AD dementia, and, interestingly, both TLR2 and MyD88 
were positively correlated with the Braak score. MyD88 was also 
negatively correlated with cognitive function.
Although TLR2 is an important member of the innate immune 
system, we found no specific inhibitor targeting TLR2. Therefore, 
through structural analysis of the interaction between TLR2 and 
MyD88, we designed a peptide corresponding to the TIDM from 
the CD loop. Since the BB loop of TLR2 interacts with the CD loop 
of MyD88, WT TIDM peptide disrupts the association between 
TLR2 and MyD88. Interestingly, the WT TIDM peptide docks in a 
way that allows it to specifically target the BB loop of TLR2, but not 
other TLRs, thereby inhibiting signaling pathways transduced by 
TLR2 only. Since the WT TIDM peptide specifically targets TLR2 
and fibrillar Aβ1-42 requires TLR2 for microglial activation (17, 
18), WT TIDM peptide inhibited the microglial NF-κB activation 
and inflammation induced only by LTA (a known agonist of TLR2) 
and fibrillar Aβ1-42, but not by MPP+, poly IC (an agonist of TLR3), 
LPS (an agonist of TLR4), flagellin (an agonist of TLR5), or CpG 
DNA (an agonist of TLR9), indicating selective inhibition of the 
TLR2 pathway by WT TIDM peptide. Moreover, consistent with 
the disruption of TLR2-MyD88 interaction, WT TIDM peptide did 
not function in the absence of TLR2.
Unmodified peptides usually have short half-lives due to rap-
id proteolysis in blood, kidneys, or liver, and/or accelerated renal 
clearance, which are the major challenges of most peptide thera-
pies. However, it has been shown that the Drosophila antennapedia 
homeodomain–derived cell-penetrating peptide penetratin, being 
rich in positively charged residues, helps cargo peptides translo-
cate into the cells, therefore avoiding rapid proteolysis (36, 37). 
Moreover, unmodified peptides do not enter into the CNS, and 
we have seen that penetratin can breach the tight endothelial net-
work and carry peptides across the blood-brain barrier (BBB) (23, 
38). Therefore, we tested the efficacy of penetratin-containing 
WT TIDM peptide in Tg mice and demonstrated that WT TIDM 
peptide reduced microglial inflammation, decreased neuronal 
apoptosis, and protected cognitive function from AD toxicity. 
Our conclusions are based on several observations. First, after 
intranasal administration, TIDM peptide entered into the hippo-
campus. Second, WT TIDM, but not mTIDM, peptide inhibited 
hippocampal activation of NF-κB and microglial inflammation 
in Tg mice. Third, WT TIDM, but not mTIDM, peptide protected 
hippocampal neurons and NMDA and AMPA receptor proteins 
from AD toxicity in Tg mice. Fourth, WT TIDM, but not mTIDM, 
peptide also improved spatial learning and memory in Tg mice. 
Furthermore, we detected no drug-related side effects (e.g., hair 
(Figure 7A), indicating the specificity of the effect. As expected, the 
induction of EAE reduced locomotor activity in mice, which was 
evidenced by heatmap analysis (Figure 7B), distance traveled (Fig-
ure 7C), rearing (Figure 7D), velocity (Figure 7E), acceleration (Fig-
ure 7F), and Rotarod performance (Figure 7G). Footprint analysis 
(Supplemental Figure 18) also indicated a decrease in stride length 
(Figure 7H) and print length (Figure 7I) and an increase in sway 
length (Figure 7J) and toe spread (Figure 7K) in EAE mice as com-
pared with normal mice. We also frequently observed dragging of 
toes in EAE mice (Supplemental Figure 18). However, intranasal 
treatment with WT TIDM, but not mTIDM, peptide improved loco-
motor activity and normalized the footprints of EAE mice (Figure 
7, A–K, and Supplemental Figure 18). Collagen- induced arthritis 
(CIA) is a widely used animal model of rheumatoid arthritis. In EAE 
mice, WT TIDM, but not mTIDM, peptide also decreased clinical 
symptoms of CIA in (Figure 7L). When we compared the means 
between groups with Dunnett’s multiple comparisons analyses, we 
found that there was a significant difference of means between the 
CIA and CIA plus WT TIDM mice (adjusted P = 0.0148 [< 0.05]). 
WT TIDM peptide also enhanced locomotor activity (Figure 7, 
N–R) and improved footprint behavior in the mice (Figure 7, S–V, 
and Supplemental Figure 19).
Discussion
Deciphering the mechanism of the disease process of AD and 
developing an effective neuroprotective therapeutic approach 
to slow down or halt the disease progression are of paramount 
importance. TLRs are known to resolve innate immune responses 
by perceiving pathogen-associated molecular patterns and endog-
enous damage-associated molecular patterns (15). Microglia in 
the CNS express most of the TLRs known to date, and earlier we 
showed that among the different TLRs, fibrillar Aβ1-42 requires 
TLR2 to stimulate microglial inflammation (17) . Accordingly, sev-
eral studies have extended this finding either by demonstrating a 
Figure 6. Intranasal delivery of WT TIDM, but not mTIDM, peptide inhib-
its neuronal apoptosis in vivo in the hippocampus and improves memory 
and learning in Tg mice. Tg mice (6 months of age) were treated intrana-
sally with WT TIDM and mTIDM peptides (0.1 mg/kg BW/2 d). (A) After 30 
days of treatment, mice were sacrificed, and hippocampal sections were 
double labeled for TUNEL and NeuN. Scale bars: 50 μm. TUNEL-positive 
cells (B, CA1; C, CA3) were counted in 2 sections (2 images/slide) from 
each of 6 different mice (n = 6) per group. †P < 0.001 versus non-Tg; ††P < 
0.001 versus Tg; 2-sample t test. (D) Hippocampal extracts from all groups 
of mice (n = 4) were immunoblotted for cleaved caspase 3. Actin was run 
as a loading control. (E) Bands were scanned, and the values (cleaved 
caspase 3/actin) are presented relative to the non-Tg control. Results 
are expressed as the mean ± SEM of 4 mice per group. †P < 0.001 versus 
non-Tg; ††P < 0.001 versus Tg; 2-sample t test. (F) Protein levels of PSD95, 
NR2A, and GluR1 were monitored in hippocampal extracts by Western blot 
analysis. Bands were scanned, and the values (G, PSD95/actin; H, NR2A/
actin; I, GluR1/actin) are presented relative to the non-Tg control. Results 
are expressed as the mean ± SEM of 4 mice per group. †P < 0.001 versus 
non-Tg; ††P < 0.001 versus Tg; 2-sample t test. Mice were tested using the 
Barnes maze (J, latency; K, number of errors made) and T-maze (L, number 
of positive turns; M, number of negative turns). (N) Short-term memory 
was also assessed by the NOR test, which is represented by the discrim-
ination index. Eight mice were used in each group, and the results were 
analyzed by 1-way ANOVA.
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Figure 7. WT TIDM, but not mTIDM, peptide protects mice from EAE and CIA. (A) EAE was induced in male C57/BL6 mice by MOG35-55 immuniza-
tion, and from 10 dpi, mice were treated with intranasal WT TIDM and mTIDM peptides (0.1 mg/kg BW/d). Mice (n = 6 per group in 2 independent 
experiments) were scored daily. As evident by 1-way, repeated-measures ANOVA, the WT TIDM peptide significantly protected mice from EAE (F2,94 
= 22.59 [>Fc = 3.093]). On day 22 after immunization, general motor activity was assessed using the EthoVision XT 13.0 Open Field Activity System 
(Noldus) (B, heatmap images representing overall motor activity; C, distance traveled; D, rearing; E, velocity; F, acceleration) and (G) Rotarod test-
ing. Footprint analysis (H, stride length; I, print length; J, sway length; K, toe spread) was also performed. (L) CIA was induced in male DBA/1J mice 
by bovine type II collagen immunization, and from 29 dpi, mice were treated with WT TIDM and mTIDM peptides (1 mg/kg BW/d) via intraperitoneal 
injection. Mice (n = 6/group in 2 independent experiments) were scored daily. Repeated-measures, 1-way ANOVA showed that the WT TIDM peptide 
significantly protected against CIA (F2,45 = 4.927 [>Fc = 3.093]). On day 60 after immunization, general motor activity was assessed using the Etho-
Vision system (M, heatmap images representing overall motor activity; N, distance traveled; O, rearing; P, velocity), Rotarod testing (Q), and grip 
strength testing (R). Footprint analysis (S, stride length; T, print length; U, sway length; V, toe spread) was also performed. Six mice (n = 6/group) 
were used in 2 independent experiments. †P < 0.001 and ††P < 0.05 versus control; ‡P < 0.001 and ‡‡P < 0.05 versus EAE or CIA by 2-sample t test. 
Data represent the mean ± SEM.
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as previously described (44). Subjects with pathological findings other 
than AD (e.g., stroke, Parkinson disease, Lewy body dementia) were 
excluded from the study.
Tissue samples and Western blot analysis. Superior frontal cortex 
(Brodmann area 9) was dissected free of white matter at autopsy on dry 
ice to prevent thawing and was maintained at −80°C until assay. Tissue 
was homogenized and processed as described previously (22). Tissue 
extracts and cell lysates (30 μg) were electrophoresed on 8% or 10% 
Bis-Tris SDS polyacrylamide gels in a continuous buffer system, trans-
ferred onto nitrocellulose membranes (Bio-Rad) with a semi-dry blotter 
(Pierce, Thermo Fisher Scientific), and immunoblotted as described 
previously (22, 49–51). Blots were converted to binary, analyzed using 
ImageJ (NIH), and normalized to the β-actin loading control.
Preparation of cTLR2. The TLR2 full-length construct (pLenti-
cMyc-DDK/Tlr2) was purchased from Origene. cTLR2 (640–784 ami-
no acids) tagged with cMyc was subcloned into a lentivector using the 
TOPO TA Cloning Kit (K5310-00; Life technologies, Thermo Fisher 
Scientific). Briefly, a Kozak sequence was incorporated upstream of 
the cTIR2 domain of TLR2. Next, cTLR2 was subcloned into the len-
tivector, followed by packaging in lentivirus using HEK293FT cells. 
After 48 hours, media were collected and concentrated with Lenti-X 
Concentrator (catalog 631231; Clontech). This concentrated lentiviral 
supernatant was used for viral transduction. The cTLR2 protein was 
isolated from the HEK293 cell lysate by passing through a Myc affini-
ty column. Purified protein was desalted and concentrated by using a 
10-kDa molecular cutoff filtration system.
SPR. To analyze the binding of TLR2 with TIDM peptides, SPR 
experiments were carried out using a Reichert 4SPR instrument. 
The binding assay was performed using a 500-kDa Carboxymethyl 
Dextran Gold Sensor Slide (Reichert Technologies) to capture TLR2. 
Protein immobilization was at a flow rate of 30 μl/min in PBS for 3 
minutes with a 0.8-mg/ml solution of TLR2. For analyte association, 
different concentrations of WT TIDM and mTIDM peptides in PBS 
running buffer were injected for 2.5 minutes at a rate of 30 μl/min, 
followed by a dissociation phase of 3 minutes. The sensor surface was 
regenerated after each dissociation cycle by allowing buffer to flow 
at 40 μl/min for a minimum of 15 minutes. Signals obtained for the 
TLR2-bound surface were subtracted by signals obtained for the ref-
erence cell according to standard procedures using Reichert system 
software. The concentration dependence of the subtracted signal was 
analyzed to determine binding affinity of TLR2 with WT TIDM and 
mTIDM peptides.
Thermal shift assays. Thermal shift assays were performed on an 
Applied Biosystems 7500 standard real-time thermal cycler machine 
as described previously (52, 53). For each reaction, purified protein 
(0.5–1 μg) was added to 18 μl of the thermal shift buffer provided with 
the kit and 1–2 μl dye. The reaction was performed in a 96-well PCR 
plate in the dark and then placed in the thermal cycler machine using 
the following 2-stage program: 1 cycle at 25°C for 2 minutes; 70 cycles 
at 27°C for 15 seconds and 26°C for 1 minute; and auto increment at 
1°C for both stages. The filter was set at ROX with no quencher filter 
and no passive filter.
In silico structural analysis. We used Deep View 3.7β2, an online 
macromolecular analytical tool of Expert Protein Analytical System 
(ExPASy), to model structures of TIR domains of different TLRs 
(TLR1, TLR2, TLR4, TLR5, TLR6, TLR7, and TLR9). In order to eval-
uate the quality of modeled structures, we used the Quality Measure-
loss, appetite loss, weight loss, untoward infection, etc.) in any of 
the TIDM-treated mice used during the course of the study. How-
ever, 1 study has shown that genetic knockdown of TLR2 acceler-
ates the cognitive decline in APP-Tg mice (39). This is definitely 
possible, as complete knockdown of TLR2 wipes out basal as well 
as induced TLR2 signaling pathways. Moreover, TLR2 has been 
shown to function via both MyD88-dependent and -independent 
pathways (40, 41), and the beauty of our finding is that the TIDM 
peptide targeted only the MyD88-dependent induced TLR2 sig-
naling pathway, without inhibiting basal TLR2 activity.
Whether or not plaques are directly related to the loss of mem-
ory in AD, amyloid plaque  is one of the pathological hallmarks of 
this disease. It is also important to note that WT TIDM, but not 
mTIDM, peptide treatment reduced hippocampal plaque load in Tg 
mice. However, at present, we do not know how WT TIDM peptide 
treatment is coupled to plaque reduction. β-Secretase 1 (BACE1) is 
the key enzyme that initiates the formation of Aβ, and it has been 
shown that inhibition of NF-κB prevents Aβ-induced BACE1 pro-
moter transactivation and that overexpression of WT or Swed-
ish mutated βAPP does not modify the transactivation of BACE1 
promoter constructs lacking the NF-κB–responsive element (42). 
Since WT TIDM peptide suppresses fibrillar Aβ–induced activation 
of NF-κB, it is possible that WT TIDM peptide reduces the plaque 
burden in Tg mice via attenuation of the NF-κB/BACE1 pathway.
There is no effective therapy for halting the progression of 
AD. Administration of different inhibitors of cholinesterase such 
as Aricept, Exelon, Razadyne, Cognex, etc., has been the stan-
dard treatment for this disease (43). However, this treatment is 
often associated with a number of side effects and unsatisfacto-
ry outcomes. Here, we have demonstrated that TLR2 and MyD88 
levels are upregulated in the CNS of patients with AD; that TLR2 
and MyD88 are positively correlated with the Braak score, that 
WT TIDM peptide targets only TLR2 without modulating other 
signaling pathways; and that after intranasal administration, WT 
TIDM peptide reaches the hippocampus, suppresses hippocam-
pal NF-κB activation, inhibits microglial inflammation, lowers 
cerebral plaque load, attenuates neuronal apoptosis, and protects 
learning and memory functions in Tg mice. These results suggest 
that selective targeting of TLR2 by intranasal WT TIDM peptide 
may have therapeutic importance in AD. Moreover, WT TIDM 
peptide also improved functional impairment and suppressed dis-
ease processes of EAE and CIA in mice. Therefore, in addition to 
AD, TIDM peptide may also open up an opportunity for the treat-
ment of other disorders.
Methods
Human subjects. Samples from 33 subjects with an antemortem clinical 
diagnosis of NCI (n = 12), MCI (n = 11), or AD (n = 10) obtained from 
the Rush Religious Order Study (RROS) (44, 45) were analyzed (Sup-
plemental Table 1). All participants agreed to a detailed annual clinical 
evaluation and brain donation upon their death.
Clinical and neuropathologic evaluations. The clinical criteria for 
the diagnosis of NCI, MCI, and AD have been reported elsewhere 
(44, 46). Final clinical and neuropsychological testing, which included 
the MMSE and a battery of 19 cognitive tests, was performed within 2 
years before the participant’s death. A GCS comprising the 19 tests was 
available for all cases (47). Braak staging of NFTs (48) was performed 
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For the T-maze test, mice were also habituated in the T-maze 
for 2 days under food-deprived conditions so that the animals would 
eat food rewards at least 5 times over a 10-minute period of training. 
During each trial, mice were placed at the starting point for 30 seconds 
and then forced to turn at the right arm of the maze, which was always 
baited with colored food chips. After each training session, the T-maze 
was thoroughly cleaned with a mild detergent. On day 3, mice were 
tested for making positive turns and negative turns. The reward side 
was always associated with a visual cue. Each time the animal ate the 
food reward, it was considered a positive turn.
NOR task. The NOR task was performed to monitor short-term 
memory as described by others (58) and us (57). Briefly, during train-
ing, the mice were placed in a square novel box (20 in. long × 8 in. high) 
surrounded with an infrared sensor. Two plastic toys (2.5–3 in. size) 
that varied in color, shape, and texture were placed in specific loca-
tions in the environment 18 inches away from each other. The mice 
were able to freely explore the environment and objects for 15 minutes 
and were then placed back into their individual home cages. After 30 
minutes, the mice were placed back into the environment, with the 
2 objects in the same locations, but now 1 of the familiar objects was 
replaced with a third novel object. The mice were again allowed to 
freely explore both objects for 15 minutes. The objects were thorough-
ly cleaned with a mild detergent after each session.
IHC. Mice were anesthetized with ketamine-xylazine injectables 
and perfused with PBS and then with 4% (w/v) paraformaldehyde 
in PBS, followed by dissection of the brain for immunofluorescence 
microscopic examination (23, 59). Briefly, samples were incubated in 
PBS containing 0.05% Tween 20 (PBST) and 10% sucrose for 3 hours 
and then 30% sucrose overnight at 4°C. Brain tissue was then embed-
ded in OCT (Tissue Tech) at –80°C and processed for conventional 
cryosectioning. Frozen sections (30-μm-thick) were treated with cold 
ethanol (–20 °C), followed by 2 rinses in PBS, blocking with 3% BSA in 
PBST, and double labeling with 2 antibodies (Supplemental Table 3). 
After 3 washes in PBST, the sections were further incubated with Cy2 
and Cy5 (Jackson ImmunoResearch Laboratories). The samples were 
mounted and observed under an Olympus IX81 fluorescence micro-
scope. Counting analysis was performed using Olympus Microsuite V 
software with the help of a touch counting module.
Fragment end-labeling of DNA. Fragment end-labeling of DNA was 
performed using a commercially available kit (TdT FragEL, Calbio-
chem) as described previously (10, 22).
ELISA for Aβ1-42 and Aβ1-40. Hippocampal tissues were homoge-
nized in TBS and pelleted for 30 minutes at 150,000 g. The pellet was 
resuspended in 3 volumes (w/v original tissue weight) of TBS plus 1% 
Triton X-100, pelleted for 30 minutes at 150,000 g, and the superna-
tant recovered and stored. Samples were assayed for protein concen-
tration and diluted 10-fold prior to performing ELISA according to the 
manufacturer’s instructions (BioLegend).
Statistics. Clinical and biochemical data on human tissues were 
compared across diagnoses using nonparametric tests (i.e., Krus-
kal-Wallis test or Fisher’s exact test, with Dunn’s correction for multiple 
comparisons), which are more robust to outliers, non-normality, and 
unequal sample sizes. A 2-tailed Spearman’s rank-order correlation was 
used to assess variable associations between cognitive test scores and 
protein optical densities. Correlations were unadjusted for demograph-
ic information (i.e., age, sex, etc.), as these metrics were not significant-
ly different between clinical groups. Statistical tests were performed 
ment Analysis (QMEAN) tool, a composite scoring tool that estimates 
the global quality of the entire model as well as the local per-residue 
value of different regions within a model. Residue-level interaction 
was evaluated by the Cβ atom potential, and long-range interactions 
were validated by the all-atom potential. A solvation potential was 
implemented to analyze the burial status of the residues. The local 
geometry of each structure was analyzed by a torsion angle potential 
over 3 consecutive amino acids. The docked pose of the TIR domains 
with either the WT TIDM or mTIDM peptide was derived from the 
pyDock rigid-body, protein-protein docking tool (https://life.bsc.es/
pid/pydockweb/).
Animals and intranasal delivery of TIDM peptides. B6SJL-Tg(APPS-
wFlLon,PSEN1*M146L*L286V)6799Vas/J–Tg (5XFAD, referred to here 
as Tg) mice were purchased from The Jackson Laboratory. Six-month-
old male Tg mice were treated intranasally with WT TIDM or mTIDM 
peptides (0.1 mg/kg BW/2 d) for 30 days. Briefly, TIDM peptides were 
dissolved in 5 μl normal saline, mice were held in supine position, and 
saline was delivered into 1 nostril using a pipetman.
Induction of chronic EAE and treatment with TIDM peptides. Male 
C57BL/6 mice were immunized with 100 μg MOG35-55 as described 
by us previously (54, 55). Mice also received 2 doses of pertussis tox-
in (150 ng/mouse) 0 and 2 days post immunization (dpi). Starting 
from 10 dpi, mice received WT TIDM or mTIDM peptides (0.1 mg/
kg BW/d) intranasally.
Induction of CIA and treatment with TIDM peptides. Male DBA/1J 
mice (8–9 weeks of age) were immunized intradermally at the base of 
the tail with 100 μg bovine type II collagen emulsified in incomplete 
Freund’s adjuvant and M. tuberculosis H37RA. On day 21 after immuni-
zation, the mice were boosted with an intraperitoneal injection of 100 
μg bovine type II collagen. Mice were treated intraperitoneally with WT 
TIDM or mTIDM peptides (1 mg/kg BW/d) starting from 29 dpi.
Preparation of fibrillar Aβ1-42. Fibrillar Aβ1-42 (AnaSpec) was 
prepared by incubating freshly solubilized peptides at 50 μM in sterile 
distilled water at 37°C for 5 days (56). Supplemental Figure 20 shows 
the morphology of fibrillar Aβ1-42.
Semiquantitative reverse transcriptase–coupled PCR analysis. Total 
RNA was isolated from hippocampus using Ultraspec II RNA Reagent 
(Biotecx Laboratories Inc.) according to the manufacturer’s protocol. 
To remove any contaminating genomic DNA, total RNA was digested 
with DNase. Semiquantitative reverse transcriptase–coupled PCR was 
performed as described earlier (23, 57) using a RT-PCR Kit (Clontech).
Real-time PCR analysis. DNase-digested RNA was analyzed by 
real-time PCR using the ABI-Prism7700 Sequence Detection System 
(Applied Biosystems) as described previously (23, 57).
EMSA. Nuclear extracts were isolated, and EMSA was carried out 
as described before (22, 23).
Barnes maze and T-maze tests. Maze experiments were performed 
as described previously by us (52, 57). Briefly, for the Barnes maze test, 
mice were trained for 2 consecutive days, followed by testing on day 
3. After each training session, the maze and escape tunnel were thor-
oughly cleaned with a mild detergent so the mice would not instinc-
tively avoid odors on familiar objects in the maze. On day 3, the maze 
was illuminated with high-wattage light that generated enough light 
and heat to motivate animals to enter into the escape tunnel, allowing 
us to measure latency (duration before all 4 paws were on the floor of 
the escape box) and errors (incorrect responses before all 4 paws were 
on the floor of the escape box).
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